ADIAL director Wendy Young files initial Form 3

ADIAL PHARMACEUTICALS, INC. director Wendy B. Young filed an initial Form 3, which is a statement of beneficial ownership for new insiders.

Rhea-AI Filing Summary

ADIAL PHARMACEUTICALS, INC. director Wendy B. Young filed an initial Form 3, which is a statement of beneficial ownership for new insiders. This filing does not report any share purchases, sales, option exercises, or other transactions, and no holdings are detailed in the provided data.

Key Terms

Form 3, reporting person, beneficial ownership

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3): initial statement of beneficial ownership"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

reporting person regulatory

""reportingPersons": [{"name": "Young Wendy B.""

beneficial ownership financial

"Form 3 is a statement of beneficial ownership for new insiders"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the ADIL Form 3 filing by Wendy B. Young show?

The Form 3 for ADIL reports that director Wendy B. Young became an insider. In the provided data, it does not list any specific share holdings, purchases, sales, or derivative positions, serving mainly as an initial ownership registration.

Did Wendy B. Young buy or sell ADIL shares in this Form 3?

No transactions are reported in this ADIL Form 3. The transaction summary shows zero buys, zero sells, and zero derivative exercises, indicating the filing is purely an initial ownership statement without trading activity disclosed.

What is the purpose of a Form 3 for ADIAL PHARMACEUTICALS, INC.?

Form 3 is the SEC’s initial statement of beneficial ownership for insiders of ADIAL PHARMACEUTICALS, INC.. It establishes baseline ownership when someone becomes a director, officer, or large shareholder, before any future Form 4 transaction reports are filed.

Does the ADIL Form 3 include any derivative securities or options?

The derivative section in this ADIL Form 3 is empty. The derivative summary shows zero derivative transactions and no remaining derivative positions, meaning no options, warrants, or similar instruments are disclosed in the provided data.

Who is the reporting person in the ADIL Form 3 filing?

The reporting person is Wendy B. Young, identified as a director of ADIAL PHARMACEUTICALS, INC.. She is listed as a reporting person but, in the provided data, has no reported transactions or detailed holdings attached to this initial filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/16/2026 - 06:10 AM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Young Wendy B.

(Last) (First) (Middle)

C/O ADIAL PHARMACEUTICALS, INC.

4870 SADLER ROAD, SUITE 300

(Street)

GLEN ALLEN, VIRGINIA 23060

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
06/11/2026

3. Issuer Name and Ticker or Trading Symbol
ADIAL PHARMACEUTICALS, INC. [ ADIL ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24, Power of Attorney, is attached.

No securities are beneficially owned.

	/s/ Matthew Davidson, Attorney-in-Fact	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)